InsidersTradesSigma
昊海生科 Stock: price and management transactions · China · SSE / SZSE (CSRC)
Follow the 昊海生科 stock price and the full insider trade history of the company, a listed equity based in China. Shares are listed on CN CN, under the authority of SSE / SZSE (CSRC). Operating in the Health Care sector, 昊海生科 has logged 8 reports. Market capitalisation: €7.1bn. The latest transaction was reported on 29 June 2026 (Sale). Among the most active insiders: 甘人宝. Every trade is free.
8
Insider Decl.
0
Thresholds
·
1 ops.
Buy Volume
·
7 ops.
Sell Volume
4Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 9,763 of 25,724 companies
58.1
score / 100
Value50
Quality66
FCF yld4.3%
Earn yld3.5%
EV/EBITDA16.2x
ROE3.4%
Gross mgn70%
Net mgn10%
Debt/EBITDA0.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 29 June 2026
Declarations8 total
8 of 8 declarations
About 昊海生科
昊海生科 is a company in the health and pharmaceutical sector, listed on the XSHG market. It focuses on the development and production of innovative pharmaceutical products.